Amryt Pharma plc logo
Amryt Pharma plc AMYT
report update icon

Quarterly report 2021-Q4
added 05-23-2026

Amryt Pharma plc Financial Ratios 2021-2011 | AMYT

Annual Financial Ratios Amryt Pharma plc

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

2547.2 -21.5 - - - - - - - - -

P/S

11.4 12.3 - - - - - - - - -

EPS

- -0.7 -0.8 -0.7 - - - - - - -

EV (Enterprise Value)

2.89 B 2.6 B 328 M 73.3 M 69.8 M 33.9 M 504 K 13.2 M 842 K 439 K 43.4 K

EBITDA per Share

-0.16 -0.29 -0.67 -0.39 - - - - - - -

EV/EBITDA

-75.0 -55.9 -6.5 -4.1 - - - - - - -

PEG

- -0.17 - - - - - - - - -

P/B

7.1 34.0 - - - - - - - - -

P/CF

163.9 83.5 - - - - - - - - -

ROE %

0.28 -158.03 -47.79 824.64 - - - - - - -

ROA %

0.12 -19.48 -11.95 -37.73 - - - - - - -

ROCE %

-5.86 -10.67 -11.88 -26.23 - - - - - - -

Current Ratio

1.8 1.1 1.3 1.0 - - - - - - -

All numbers in USD currency

Quarterly Financial Ratios Amryt Pharma plc

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

- - - - - - - - -0.66 - - - -0.83 - - - -0.67 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- - - - -0.16 - - - -0.29 - - - -0.67 - - - -0.39 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-205.54 -205.54 -205.54 -205.54 619.10 618.82 618.82 618.82 -158.03 - - - -47.79 - - - 824.64 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-31.31 -31.31 -31.31 -31.31 0.12 - - - -19.48 - - - -11.95 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-28.41 -28.41 -28.41 -28.41 459.47 465.33 465.33 465.33 -10.67 - - - -11.88 - - - 487.88 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

- - - - 1.8 - - - 1.1 - - - 1.3 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Amryt Pharma plc, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
CytomX Therapeutics CytomX Therapeutics
CTMX
$ 2.72 2.23 % $ 375 M usaUSA
Citius Pharmaceuticals Citius Pharmaceuticals
CTXR
$ 0.53 0.41 % $ 5.86 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 25.87 1.41 % $ 2.45 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 2.06 15.73 % $ 16.5 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 65.91 0.41 % $ 7.92 M usaUSA
Daré Bioscience Daré Bioscience
DARE
$ 0.85 4.7 % $ 9.5 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 11.76 1.82 % $ 1.64 B franceFrance
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 8.27 0.85 % $ 389 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.67 0.38 % $ 3.57 B usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 6.26 1.29 % $ 80.3 M usaUSA
Dyadic International Dyadic International
DYAI
$ 0.44 0.49 % $ 15.9 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.57 0.19 % $ 228 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 4.21 18.26 % $ 23.9 M usaUSA
Enlivex Therapeutics Ltd. Enlivex Therapeutics Ltd.
ENLV
$ 0.5 4.73 % $ 22.8 M israelIsrael
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
$ 13.18 4.27 % $ 281 K usaUSA
Entera Bio Ltd. Entera Bio Ltd.
ENTX
$ 2.91 8.18 % $ 134 M israelIsrael
Equillium Equillium
EQ
$ 1.63 0.31 % $ 93.4 M usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
$ 51.49 0.02 % $ 1.39 B usaUSA
Evogene Ltd. Evogene Ltd.
EVGN
$ 0.4 7.89 % $ 3.15 M israelIsrael
Exelixis Exelixis
EXEL
$ 58.41 0.91 % $ 15.9 B usaUSA
EyePoint Pharmaceuticals EyePoint Pharmaceuticals
EYPT
$ 3.27 3.32 % $ 240 K usaUSA
Fate Therapeutics Fate Therapeutics
FATE
$ 2.37 0.63 % $ 282 M usaUSA
Fortress Biotech Fortress Biotech
FBIO
$ 2.14 1.38 % $ 59.7 M usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 10.65 0.5 % $ 304 M usaUSA
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 3.57 1.42 % $ 225 M usaUSA
Fulcrum Therapeutics Fulcrum Therapeutics
FULC
$ 3.7 0.27 % $ 234 M usaUSA
Galectin Therapeutics Galectin Therapeutics
GALT
$ 3.88 0.13 % $ 248 M usaUSA
Geron Corporation Geron Corporation
GERN
$ 1.23 0.81 % $ 820 M usaUSA
Gilead Sciences Gilead Sciences
GILD
$ 149.05 0.85 % $ 185 B usaUSA
Greenwich LifeSciences Greenwich LifeSciences
GLSI
$ 18.05 2.07 % $ 244 M usaUSA
Genmab A/S Genmab A/S
GMAB
$ 35.67 0.3 % $ 2.31 B danmarkDanmark
Genprex Genprex
GNPX
$ 2.92 2.46 % $ 2.72 M usaUSA
Gossamer Bio Gossamer Bio
GOSS
$ 11.85 2.33 % $ 2.71 B usaUSA
GeoVax Labs GeoVax Labs
GOVX
$ 0.33 0.28 % $ 316 K usaUSA
Grifols, S.A. Grifols, S.A.
GRFS
$ 7.31 0.21 % $ 4.97 B spainSpain
GlaxoSmithKline plc GlaxoSmithKline plc
GSK
$ 48.17 0.93 % $ 195 B britainBritain
GT Biopharma GT Biopharma
GTBP
$ 6.47 0.22 % $ 35.7 M usaUSA
Halozyme Therapeutics Halozyme Therapeutics
HALO
$ 110.4 0.1 % $ 13.2 B usaUSA
Hutchison China MediTech Limited Hutchison China MediTech Limited
HCM
$ 14.63 3.39 % $ 12.6 B chinaChina
Harmony Biosciences Holdings Harmony Biosciences Holdings
HRMY
$ 39.26 0.1 % $ 2.26 B usaUSA
Heron Therapeutics Heron Therapeutics
HRTX
$ 0.31 2.45 % $ 51.7 M usaUSA
iBio iBio
IBIO
$ 1.18 0.85 % $ 123 M usaUSA
ImmuCell Corporation ImmuCell Corporation
ICCC
$ 9.8 0.61 % $ 88.5 M usaUSA
IDEAYA Biosciences IDEAYA Biosciences
IDYA
$ 38.42 1.48 % $ 3.4 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.8 0.54 % $ 121 M germanyGermany
Inhibikase Therapeutics Inhibikase Therapeutics
IKT
$ 2.06 1.73 % $ 203 M usaUSA
Immutep Limited Immutep Limited
IMMP
$ 4.65 0.21 % $ 6.77 B australiaAustralia
Immunome Immunome
IMNM
$ 21.51 0.41 % $ 1.88 B usaUSA
Immuron Limited Immuron Limited
IMRN
$ 1.16 2.59 % $ 268 M australiaAustralia
Immatics N.V. Immatics N.V.
IMTX
$ 8.78 2.57 % $ 1.07 B germanyGermany